



June 10, 2014

Company: Fuji Pharma Co., Ltd.
Representative: Hirofumi Imai,
President & CEO
Ticker code: 4554, TSE (1st section)
Contact: Corporate Planning Division

Press Release: Transfer of approval for marketing authorization of “Optiray®”
non ionic ioversol contrast agent

Fuji Pharma Co., Ltd. (“Fuji”) is pleased to announce that Fuji has completed transfer of marketing authorization of Optiray®, non ionic ioversol contrast agent, from Mallinckrodt Japan Co., Ltd. (Mallinckrodt Japan) on June 10, 2014.

Fuji is now distributing and selling Optiray® from December 1, 2013, as posted in our press release dated October 15, 2013 (“Announcement of Transfer of Distribution and Sales of Optiray® right”). Also, Fuji is collecting and providing specialized information of Optiray® by newly established Imaging and Contrast Media Group in the Marketing Division as posted in our press release dated December 2, 2013.

From June 10, 2014, with this transfer of approval for marketing authorization of Optiray® hereinabove, Fuji takes responsible for supplying products of Optiray® and collecting and providing its information in place of Mallinckrodt Japan.

Fuji will increase its presence in the contrast agent market in Japan and increase its enterprise value particularly in the injection business and the acute care field by adding Optiray® onto our contrast agent family, Oypalomin® injection (iopamidol contrast agent) and Iopaque (iohexol contrast agent).